Invest in Heidi
Archangel Ventures has secured additional allocation in Heidi’s $65 Million USD Series B funding round.
This is available exclusively to Australian investors who qualify as sophisticated or professional investors under Australian law.
Heidi is redefining how clinicians deliver care by embedding AI directly into their clinical workflows. Today, Heidi automates clinical note-taking and task generation at the point of care. It’s doubling healthcare’s capacity without dehumanising it. When AI chases efficiency over humanity, care suffers. When it works with clinicians - not against them - they can focus fully on patients, and care reaches more people while staying deeply human.
We’ve backed Heidi since its pre-seed round and have watched it evolve from a promising local AI startup into one of Australia’s most exciting healthtech companies, now expanding globally including in the US and the UK.
Heidi is used by tens of thousands of clinicians from over 200 medical specialties, supporting over 73 million consults and returning 18 million hours to the frontline
This is an opportunity for clinicians, patients, and early supporters to share in the team’s success.
Why this round stands out:
-
Clear Product-Market Fit: High user activity, strong enterprise traction and improving user metrics.
-
Massive Market Tailwinds: Global shortage of clinicians and rising healthcare demand create an urgent need for productivity-enhancing tools.
-
Proven Execution: The team has repeatedly delivered against ambitious forecasts and outperformed competitors in local and international markets.
-
Global Category Leadership: With proven traction in the UK and early momentum in the US, Heidi is positioned to define the AI Care Partner category worldwide, evolving from medical scribing to full workflow automation for clinicians.
Heidi is not just digitizing healthcare, it’s transforming the economics of care delivery by helping clinicians do more with less.
We believe Heidi has the potential to become a global healthcare infrastructure company - empowering clinicians, improving patient outcomes, and reshaping how healthcare is delivered.
AFR's coverage on the Series B Raise
Capital Brief coverage of the allocation
We are taking expressions of interest until midnight AEDT, Friday 7 November.
* Note: This round is only open to sophisticated investors under Australian law